Insulet Corporation $PODD Shares Bought by Nordea Investment Management AB

Key Points

• Nordea Investment Management AB increased its stake in Insulet by 35.0% in Q4, buying 142,922 shares to hold 551,133 shares (about 0.78% of the company) valued at roughly $157.13 million.
• Insulet reported a Q1 beat with EPS of $1.55 versus $1.48 expected and revenue of $783.8 million (up 31.2% year-over-year), while analysts trimmed targets but maintain a consensus rating of Moderate Buy and an average target of $354.24.
• Director Michael R. Minogue purchased 2,030 shares at $246.23 (≈$499,847), raising his holdings to 17,483 shares—a 13.14% increase in his ownership.

Nordea Investment Management AB raised its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 35.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 551,133 shares of the medical instruments supplier's stock after buying an additional 142,922 shares during the period. Nordea Investment Management AB owned approximately 0.78% of Insulet worth $157,128,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PODD. Sage Mountain Advisors LLC raised its stake in shares of Insulet by 4.6% in the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier's stock valued at $229,000 after acquiring an additional 33 shares in the last quarter. Glenmede Investment Management LP boosted its holdings in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier's stock valued at $708,000 after purchasing an additional 35 shares during the period. Curi Capital LLC grew its stake in Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock worth $1,365,000 after purchasing an additional 36 shares in the last quarter. WINTON GROUP Ltd increased its holdings in Insulet by 0.9% during the 3rd quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier's stock worth $1,261,000 after purchasing an additional 37 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd increased its holdings in Insulet by 28.7% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier's stock worth $55,000 after purchasing an additional 39 shares during the period.

Insider Buying and Selling at Insulet

In related news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director owned 17,483 shares of the company's stock, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.39% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PODD shares. Truist Financial decreased their price objective on Insulet from $390.00 to $360.00 and set a "buy" rating for the company in a research note on Thursday, February 19th. TD Cowen lowered shares of Insulet from a "buy" rating to a "hold" rating and set a $294.00 target price on the stock. in a research note on Monday, January 26th. Raymond James Financial reduced their target price on shares of Insulet from $385.00 to $355.00 and set an "outperform" rating on the stock in a report on Thursday, February 19th. Barclays reiterated an "underweight" rating and set a $286.00 price target on shares of Insulet in a report on Thursday, February 19th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Insulet from $415.00 to $340.00 and set an "overweight" rating on the stock in a research report on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $354.24.

Insulet Trading Down 0.7%

PODD opened at $227.10 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. Insulet Corporation has a one year low of $216.49 and a one year high of $354.88. The company has a market cap of $15.99 billion, a P/E ratio of 64.89, a PEG ratio of 1.36 and a beta of 1.42. The business's 50-day simple moving average is $252.11 and its 200-day simple moving average is $292.83.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.07. The firm had revenue of $783.80 million during the quarter, compared to analysts' expectations of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm's revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.15 earnings per share. As a group, equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.